🇺🇸 Infliximab [infliximab biosimilar 3] in United States

Infliximab [infliximab biosimilar 3] (infliximab-infliximab-biosimilar-3) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Infliximab [infliximab biosimilar 3] in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in United States

Frequently asked questions

Is Infliximab [infliximab biosimilar 3] approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Infliximab [infliximab biosimilar 3] in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Infliximab [infliximab biosimilar 3] cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.